STOCK TITAN

Kairos Pharma, Ltd. (KAPA) Stock News, Apr-Sep 2025

KAPA NYSE

Kairos Pharma reports news as a clinical-stage biopharmaceutical company developing cancer therapeutics designed to address drug resistance and immune suppression. Its updates center on ENV-105, also described as carotuximab, a CD105-targeting antibody program studied in prostate cancer and non-small cell lung cancer, along with broader oncology pipeline and structural-biology themes.

Company news also covers scientific conference presentations, clinical-data disclosures, annual meeting and shareholder matters, award recognition, and annual filing updates. Kairos has stated that ENV-105 has not been approved as safe or effective by the FDA or comparable foreign regulators.

Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has announced a virtual KOL event scheduled for September 18th, 2025 to discuss interim efficacy results of its Phase 2 trial for ENV105 in advanced prostate cancer treatment. The event will feature distinguished experts including the company's CSO and leading oncologists from prestigious institutions.

The announcement follows positive interim safety results from July 2025, where ENV105, a first-in-class CD105 antagonist, demonstrated good tolerability when combined with apalutamide. The trial showed no dose-limiting toxicities, unexpected adverse events, or Grade 3/4 toxicities in the first 10 patients.

ENV105 aims to address the growing challenge of castration-resistant prostate cancer, affecting one million men annually in the US who develop resistance to current hormone therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.70%
Tags
none
-
Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming World Lung Cancer Conference, where initial Phase 1 data for ENV105 in non-small cell lung cancer will be presented. The presentation, led by Principal Investigator Dr. Karen Reckamp, will focus on the combination therapy of ENV105 with osimertinib for treating EFGR-mutated non-small cell lung cancer.

The open-label trial aims to evaluate the safety and tolerability of this combination therapy. The conference will take place from September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
-
Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO and Chairman Dr. John Yu will deliver a corporate overview presentation, which will be available on-demand starting at 7:00 AM Eastern Time on September 5, 2025. The conference will take place at the Lotte New York Palace Hotel from September 8-10, 2025.

Investors can access the presentation webcast through the company's investor relations website, with a replay available for 90 days. One-on-one meetings with Dr. Yu can be scheduled through the conference registration system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
conferences
Rhea-AI Summary

Kairos Pharma (NYSE American:KAPA), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, at the Lotte New York Palace Hotel in New York City.

The company's CEO and Chairman, Dr. John Yu, will be available for one-on-one meetings throughout the conference. The presentation will be accessible virtually through the company's website at kairospharma.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.84%
Tags
none
-
Rhea-AI Summary

Kairos Pharma (NYSE American:KAPA) has reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer (mCRPC) patients. The interim analysis from the first ten patients showed the drug was well-tolerated when combined with apalutamide, with no dose-limiting toxicities or unexpected adverse events.

The randomized Phase 2 trial aims to enroll 100 patients across three medical centers, evaluating ENV-105's safety and early efficacy in men whose disease has progressed despite hormone-based therapies. Interim efficacy data is expected in September 2025, and the company plans to discuss potential Phase 3 study design with regulators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
70.78%
Tags
-
Rhea-AI Summary
Kairos Pharma (NYSE: KAPA) presented new data on its investigational cancer immunotherapy KROS101 at ASCO 2025. The study demonstrated KROS101's effectiveness as a small molecule GITR ligand agonist with dual mechanisms of action. Key findings showed KROS101 enhanced T cell function, boosted immune response through increased cytokine production, and reduced T reg populations to reverse immune system suppression. Notably, KROS101 outperformed the previously clinically tested anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration, T reg decrease, tumor cell cytotoxicity enhancement, and prevention of T cell exhaustion. CEO John Yu emphasized these results support further study of KROS101 as a promising cancer treatment solution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.51%
Tags
none
Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City. The company's CEO and Chairman, John Yu, MD, will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Interested participants can register for meetings by contacting John Perez at jperez@dboralcapital.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, scheduled for May 30-June 3, 2025, in Chicago. The company will present a poster on June 2 titled 'Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity.' CEO John Yu expressed enthusiasm about sharing data on their platform assets at this prestigious oncology meeting, highlighting KROS 101's potential in optimizing cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
none
-
Rhea-AI Summary

Kairos Pharma (NYSE: KAPA) provided a stockholder update highlighting its clinical progress and future outlook. The company is conducting two clinical trials for its lead drug ENV105: a Phase 2 trial for prostate cancer and a Phase 1 trial for EGFR-dependent non-small cell lung cancer. The company received an $876,000 Department of Defense grant for biomarker studies.

Trial sites have expanded beyond Cedars Sinai Hospital to include the University of Utah and City of Hope, with safety and interim efficacy results expected by Q2 2025. The company is also developing KROS101, a GITR ligand small molecule agonist for cancer treatment, with data presented at multiple scientific conferences.

The company maintains a strong financial position through recent private placement and non-dilutive funding, with research coverage from multiple investment banks including EF Hutton and HC Wainwright.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
Rhea-AI Summary

Kairos Pharma (NYSE American: KAPA) has received a $876,000 Department of Defense grant to support research identifying biomarkers in non-small cell lung cancer patients who develop resistance to osimertinib treatment. The grant was awarded to Cedars-Sinai Medical Center to support research in Dr. Neil Bhowmick's laboratory.

The company is currently conducting a Phase 1 trial of its lead compound ENV105 in combination with osimertinib for EGFR-driven lung cancer patients who fail to respond to single-agent osimertinib. The funded research aims to develop strategies for early detection of drug resistance and identify patients who would benefit most from ENV105 treatment, potentially improving overall survival and quality of life for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.80%
Tags
none

FAQ

What is the current stock price of Kairos Pharma (KAPA)?

Kairos Pharma (KAPA) last closed at $0.4359.

What is the market cap of Kairos Pharma (KAPA)?

The market cap of Kairos Pharma (KAPA) is approximately $2.0M.